In conjunction with published data showing that blockage of the PI3K pathway with the dual inhibitor NVP-BEZ235 does not appreciably affect survival, clonogenic growth and differentiation of normal CD34 positive cells [42], the profound antileukemic activity against Ph+ ALL indicates a pivotal role of the PI3K pathway in our ALL cells. The gene discussed is CD34; the disease is acute lymphoblastic leukemia.